Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/8932
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sulaiman, Andri Sanityoso | - |
dc.contributor.author | Indrasari, Nuri Dyah | - |
dc.contributor.author | Hustrini, i Made | - |
dc.contributor.author | Rachmani, Desti | - |
dc.date.accessioned | 2024-12-13T07:59:50Z | - |
dc.date.available | 2024-12-13T07:59:50Z | - |
dc.date.issued | 2024-04 | - |
dc.identifier.citation | Original Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/8932 | - |
dc.description.abstract | Background: Point of care is laboratory testing conducted close to the site of the patient. Point of care assessment is essential to detect and treat the hepatitis C virus in a single visit. The potential use of Genedrive extends to remote areas and key populations Therefore, there is a need for a simple, and cost-effective examination of methods, such as Genedrive. Genedrive is a rapid and low-cost diagnostic tool for the identification and treatment selection of infectious diseases. The World Health Organization targets to eliminate hepatitis by 2030, which decreases infections by 90%, and decreases deaths by 65%. Point of care could play a significant role in contributing to the elimination of hepatitis C. Chronic kidney disease (CKD) patients on hemodialysis are among the population at risk of hepatitis C due to nosocomial transmission. This study aimed to assess the role of Genedrive in measuring hepatitis C in chronic hepatitis C patients with chronic kidney disease on hemodialysis. Methods: This study used a cross-sectional design. There were 64 CKD on Hd patients in Cipto Mangunkusumo Hospital tested by Genedrive. ROC analysis was conducted to assess significant hepatitis C among chronic kidney disease on hemodialysis. Results: The calculated detection limit of Genedrive was 3.1x103 IU/mL. Genedrive HCV assay showed 90.6% sensitivity, 96.8% specificity, 92% negative predictive value, and 97% positive predictive value to detect HCV, 10.36 positive likelihood ratio, and 0.09 negative likelihood ratio. Conclusion: Genedrive could be a simple and reliable point of care method to detect hepatitis C with chronic kidney disease on hemodialysis. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Acta Medica Indosiana | en_US |
dc.subject | Hepatitis C | en_US |
dc.subject | chronic kidney disease | en_US |
dc.subject | hemodialysis | en_US |
dc.subject | genedrive | en_US |
dc.subject | point of care | en_US |
dc.title | The Role of Genedrive in Point of Care Method For Hepatitis C Elimination in Hemodialysis Center | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 56 NO 2 2024 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
185-190.pdf | 452.28 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.